Kyowa Kirin Co., Ltd. is a Japan-based specialty biopharmaceutical company focused on the research, development, manufacturing, and commercialization of prescription medicines, with an emphasis on biologics and targeted therapies. Headquartered in Tokyo, the company operates globally across Japan, Asia, Europe, and North America. Kyowa Kirin originated from the merger of Kyowa Hakko’s pharmaceutical business and Kirin Pharma, and later adopted its current name after operating as Kyowa Hakko Kirin.
The company’s R&D centers on therapeutic areas such as oncology, nephrology, immunology/inflammation, and rare diseases. Kyowa Kirin is known for expertise in antibody engineering and bioprocess development, supporting the development of monoclonal antibodies and other advanced biologics. Its activities span early discovery through clinical development and commercial supply, with a track record of partnerships and licensing agreements to advance pipeline programs and broaden market access.
To provide comprehensive coverage, we aggregate data and news under the name Kyowa Kirin, encompassing the following company names, divisions, and related entities:
Kyowa Hakko Kirin.
This list encompasses current and former names, alternate names, and key divisions associated with Kyowa Kirin, ensuring you can easily find all relevant information under a single, unified profile.